Literature DB >> 10648593

Liver transplantation. American Association for the Study of Liver Diseases.

R L Carithers1.   

Abstract

Liver transplantation has revolutionized the care of patients with end-stage liver disease. Liver transplantation is indicated for acute or chronic liver failure from any cause. Because there are no randomized controlled trials of liver transplantation versus no therapy, the efficacy of this surgery is best assessed by carefully comparing postoperative survival with the known natural history of the disease in question. The best examples of this are in primary biliary cirrhosis and primary sclerosing cholangitis, for which well-validated disease-specific models of natural history are available. There are currently relatively few absolute contraindications to liver transplantation. These include severe cardiopulmonary disease, uncontrolled systemic infection, extrahepatic malignancy, severe psychiatric or neurological disorders, and absence of a viable splanchnic venous inflow system. One of the most frequently encountered contraindications to transplantation is ongoing destructive behavior caused by drug and alcohol addiction. The timing of the surgery can have a profound impact on the mortality and morbidity of patients undergoing liver transplantation. Because of the long waiting lists for donor organs, the need to project far in advance when transplantation might be required has proven to be one of the greatest challenges to those treating patients with end-stage liver disease. Three important questions must be addressed in a patient being considered for liver transplantation: (1) when should the patient be referred for possible transplantation? (2) when should the patient be listed for transplantation? and (3) when is the patient too sick to have a reasonable chance of surviving the perioperative period?

Entities:  

Mesh:

Year:  2000        PMID: 10648593     DOI: 10.1002/lt.500060122

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  16 in total

Review 1.  Hepatic encephalopathy in liver cirrhosis: pathogenesis, diagnosis and management.

Authors:  T Gerber; H Schomerus
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

Review 2.  Developments in liver transplantation.

Authors:  J Neuberger
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 3.  Hepatitis B virus infection in liver transplant candidates and recipients.

Authors:  Patrick Yachimski; Raymond T Chung
Journal:  MedGenMed       Date:  2005-04-18

4.  Age is not a contraindication for orthotopic liver transplantation: a single institution experience with recipients older than 75 years.

Authors:  C Burcin Taner; Ryan L Ung; Barry G Rosser; Jaime Aranda-Michel
Journal:  Hepatol Int       Date:  2011-06-18       Impact factor: 6.047

5.  Long-term quality of life of liver transplant recipients beyond 60 years of age.

Authors:  G Werkgartner; D Wagner; S Manhal; A Fahrleitner-Pammer; H J Mischinger; M Wagner; R Grgic; R E Roller; D Kniepeiss
Journal:  Age (Dordr)       Date:  2013-03-26

6.  MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study.

Authors:  F Botta; E Giannini; P Romagnoli; A Fasoli; F Malfatti; B Chiarbonello; E Testa; D Risso; G Colla; R Testa
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

7.  Recipient ineligibility after liver transplantation assessment: a single centre experience.

Authors:  Aman Arya; Roberto Hernandez-Alejandro; Paul Marotta; Julia Uhanova; Natasha Chandok
Journal:  Can J Surg       Date:  2013-06       Impact factor: 2.089

Review 8.  AASLD clinical practice guidelines: a critical review of scientific evidence and evolving recommendations.

Authors:  Christopher Koh; Xiongce Zhao; Niharika Samala; Sasan Sakiani; T Jake Liang; Jayant A Talwalkar
Journal:  Hepatology       Date:  2013-10-18       Impact factor: 17.425

9.  Liver transplant candidacy unsuitability: a review of the British Columbia experience.

Authors:  Jaber Alali; Alnoor Ramji; Jin K Ho; Charles H Scudamore; Siegfried R Erb; Elsie Cheung; Bina Kopit; Clare A Bannon; Stephen W Chung; John G Soos; Andrezj K Buczkowski; Eileen M Brooks; Urs P Steinbrecher; Eric M Yoshida
Journal:  Can J Gastroenterol       Date:  2006-02       Impact factor: 3.522

10.  Portal hypertensive colopathy is associated with portal hypertension severity in cirrhotic patients.

Authors:  Antonio Diaz-Sanchez; Oscar Nuñez-Martinez; Cecilia Gonzalez-Asanza; Ana Matilla; Beatriz Merino; Diego Rincon; Inmaculada Beceiro; Maria Vega Catalina; Magdalena Salcedo; Rafael Bañares; Gerardo Clemente
Journal:  World J Gastroenterol       Date:  2009-10-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.